Today, at all four of our wholly-owned central laboratory testing facilities (United States, Netherlands, China, and Singapore), we at Eurofins Central Laboratory, a division of Eurofins BioPharma Services, wear red with the American Heart Association to aide in uniting the world from continent to continent in effort of bringing awareness to our friends, families, and colleagues suffering from cardiovascular-related diseases (CVD). Diseases under this remit include, but are not limited to, defects at birth, heart rhythm complications, and abnormal blood vessel conditions.
On January 27th, Eurofins Central Laboratory recognizes World Leprosy Day with the World Health Organization (WHO). Also known as Hansen’s disease, Leprosy is a chronic infectious disease caused by Mycobacterium Leprae. This disease affects the skin, peripheral nerves, mucus membranes of the upper respiratory tract, and eyes. Individuals affected will experience sensory loss in these affected areas as well as damaged thickened nerves.
Today we at Eurofins Central Laboratory recognize a rare neurological disorder known as Moebius Syndrome.
While we have numerous symptomatic treatments today, there is still no cure for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. There are more than 600 neurodegenerative diseases alone that affect the brain, spine, and peripheral nervous system. While diseases like Parkinson’s affect motor functions, Alzheimer’s is a progressive disease that destroys memory and other mental functions.
Celebrating Thirty Years of Good Laboratory Practice
The GLP (Good Laboratory Practice) Testing Facility of Eurofins Central Laboratory in Breda, The Netherlands has been accredited for OECD GLP for over 30 years. It all started at the BCO Centre for Research (B for Bergschot 71, the street address ever since) with the first inspection by the Dutch Health Care Inspectorate in June 1988. Over the years, BCO underwent several transformations and evolved into becoming one of the Eurofins Central Laboratory facilities, keeping the GLP Test Facility embedded in the Breda Clinical Laboratory.
Throughout the month, Eurofins Central Laboratory, a member of Eurofins BioPharma Services, stands with the American Cancer Society to recognize January as Cervical Cancer Awareness Month. According to the World Health Organization (WHO):
At Eurofins BioPharma Services, we feel this FDA press release, as a Christmas gift that came early! After working on multiple protocols, across multiple clients, we couldn't be happier to see the continued evolution of treatment solutions for this rare disease (around 2 cases per million). Prior to the first treatment being released in 2007, life expectancy of patient diagnosed with PNH was only ten years, with poor quality of life throughout that time. With the significant resource dedication of years of effort and capital, our peers and colleagues throughout the clinical trial industry have allowed patients to have:
Currently, there aren't any globally-approved pharmaceutical treatments for Stress Urinary Incontinence (SUI). With a predominately female patient population ranging in the hundreds of millions of people worldwide, this provides them with only surgical and physical therapy-based options, limiting their choice of solutions. While effective for some, there can be challenges that come with the invasive nature of surgical procedures, as well as non-compliance with the length of time required for successful physical therapy outcomes.